Vascular toxicities of cancer therapies: the old and the new–an evolving avenue
Since the late 1990s, there has been a steady decline in cancer-related mortality, in part
related to the introduction of so-called targeted therapies. Intended to interfere with a specific …
related to the introduction of so-called targeted therapies. Intended to interfere with a specific …
Hypertension and prohypertensive antineoplastic therapies in cancer patients
DCH Van Dorst, SJH Dobbin, KB Neves… - Circulation …, 2021 - Am Heart Assoc
The development of a wide range of novel antineoplastic therapies has improved the
prognosis for patients with a wide range of malignancies, which has increased the number …
prognosis for patients with a wide range of malignancies, which has increased the number …
Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy
SA Virani, S Dent, C Brezden-Masley, B Clarke… - Canadian Journal of …, 2016 - Elsevier
Modern treatment strategies have led to improvements in cancer survival, however, these
gains might be offset by the potential negative effect of cancer therapy on cardiovascular …
gains might be offset by the potential negative effect of cancer therapy on cardiovascular …
[HTML][HTML] Vascular complications of cancer chemotherapy
Abstract Development of new anticancer drugs has resulted in improved mortality rates and
5-year survival rates in patients with cancer. However, many of the modern chemotherapies …
5-year survival rates in patients with cancer. However, many of the modern chemotherapies …
[HTML][HTML] Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events
The vascular endothelial growth factor (VEGF) signaling pathway (VSP) fulfills a cardinal
role in endothelial cells and its inhibition has profound cardiovascular impact. This is true not …
role in endothelial cells and its inhibition has profound cardiovascular impact. This is true not …
Cardiotoxic effects of angiogenesis inhibitors
The development of new therapies for cancer has led to dramatic improvements in
survivorship. Angiogenesis inhibitors represent one such advancement, revolutionising …
survivorship. Angiogenesis inhibitors represent one such advancement, revolutionising …
[HTML][HTML] Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer
ME Cabanillas, S Takahashi - Seminars in Oncology, 2019 - Elsevier
Lenvatinib is a multikinase inhibitor of vascular endothelial growth factor (VEGF) receptors 1–
3, fibroblast growth factor receptors 1–4, RET, KIT, and platelet-derived growth factor …
3, fibroblast growth factor receptors 1–4, RET, KIT, and platelet-derived growth factor …
Tumor-derived extracellular vesicles regulate cancer progression in the tumor microenvironment
Q Bao, Q Huang, Y Chen, Q Wang, R Sang… - Frontiers in molecular …, 2022 - frontiersin.org
Extracellular vesicles (EVs) are nanosized particles released by numerous kinds of cells,
which are now increasingly considered as essential vehicles of cell-to-cell communication …
which are now increasingly considered as essential vehicles of cell-to-cell communication …
VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes
Although VEGF (vascular endothelial growth factor) inhibitors (VEGFIs), are effective
anticancer therapies, they cause hypertension through unknown mechanisms. We …
anticancer therapies, they cause hypertension through unknown mechanisms. We …
Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition
This process is regulated by growth factors of which VEGFA–VEGFR2 plays a key role. 7
Inhibition of angiogenesis, by targeting VEGF–VEGFR signaling, has revolutionized cancer …
Inhibition of angiogenesis, by targeting VEGF–VEGFR signaling, has revolutionized cancer …